

Cancer research test targets tumor-suppressor protein, 1/14

written by CAP TODAY
January 17, 2014

January 2014—Spring Bioscience has added the Anti-PTEN (SP218) rabbit monoclonal immunohistochemistry antibody to its portfolio of antibodies for cancer research.

Spring's internal comparison studies demonstrated that SP218 provides more accurate, sensitive, and specific detection compared with similar research-use-only tests on the market. Samples from more than 100 cases of primary prostate and colon cancer showed 100 percent concordance for PTEN loss among Spring's SP218 and the leading commercially available PTEN research-use-only tests, according to Spring.

The Anti-PTEN (SP218) rabbit monoclonal antibody for IHC on formalin-fixed, paraffin-embedded tissue is available in 0.1-, 0.5-, and 1.0-mL concentrate configurations, as well as a 7-mL ready-to-use configuration. Recommended staining protocols are available for manual, semiautomated, and Ventana Discovery XT platforms for decreased assay development times.

For research use only.

Spring Bioscience, 800-787-6896



©2026 CAP TODAY, all rights reserved.